Drug Profile


Alternative Names: Oral Peripheral Mu Opioid Receptor Antagonist; TD-1211

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Aza compounds; Benzamides; Cyclohexanes; Heterocyclic bicyclo compounds; Laxatives; Small molecules; Tropanes
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation

Most Recent Events

  • 14 Aug 2015 Phase-II development is ongoing for opioid-induced constipation in USA
  • 02 Jun 2014 Theravance Biopharma is formed as a spin-off of Theravance
  • 23 May 2014 Theravance completes a phase I trial in healthy volunteers in USA (NCT01702194)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top